National Agri-Food Biotechnology Institute (NABI), Mohali, is an autonomous R&D Institute under Department of Biotechnology, Government of India. The institute is establishing a state of art facility in the area of genomics (ABI 3730xl, RT-PCR, DNA analyzer, bioanalyzer, liquid handling system, automated DNA extraction system, LCM, Mass-Array (sequenom), etc), proteomics (MALDI-TOF-TOF, Q-TOF, nano-LC, HPLC, GCMS-MS, HP-TLC, UPLC, etc.), high performance computing facility, and food science (NIR, FTIR, SEM, etc.).The institute carries out cutting edge research at the interface of agricultural biotechnology, bioinformatics, food processing, and nutritional sciences.
Cerulean Pharma, a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Cerulean's lead nanoparticle-drug conjugate, CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer.